Treatment of Patients with Chronic Hepatitis B with Adefovir Dipivoxil

Adefovir dipivoxil, a nucleotide analog of adenosine monophosphate, is an antiviral agent that suppresses hepatitis B virus (HBV) replication through inhibition of DNA polymerase and by chain termination. To determine the effectiveness of adefovir, three populations of patients with chronic hepatitis B patients were studied: hepatitis B e antigen (HBeAg)-positive patients, HBeAg-negative patients, and patients with lamivudine-resistant tyrosine-methionine-asparate-aspartate (YMDD) mutants. All three groups of patients were treated for 48 weeks with adefovir 10 mg/d, and significant reduction in serum HBV DNA and normalization of serum alanine aminotransferase (ALT) were noted. Significant improvement in liver histology was noted in HBeAg-positive and in HBeAg-negative patients. Significant HBeAg loss and HBeAg seroconversion rates were noted in HBeAg-positive patients and in lamivudine-resistant patients. No major drug-related side effects were noted. Adefovir 10 mg/d orally is safe and effective for treatment of chronic hepatitis B.

KEYWORDS

Adefovir dipivoxil - lamivudine - chronic hepatitis B - HBeAg negative - HBeAg positive - lamivudine-resistant YMDD mutant

REFERENCES

• 1 Hepatitis B. Fact sheet WHO/204. Geneva; World Health Organization October 2000 www.who.int/inffs/en/fact204.htm; accessed on October 13, 2003
• 2 Manns M P. Current state of interferon therapy in the treatment of chronic hepatitis B.  Semin Liver Dis. 2002;  22 7-13
• 3 Manesis E K, Hadziyannis S J. Interferon α treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B.  Gastroenterology. 2001;  121 101-109
• 4 Hadziyannis S J, Papatheodoridis G V, Vassilopoulos D. Treatment of HBeAg-negative chronic hepatitis B.  Semin Liver Dis. 2003;  23 81-88
• 5 Perrillo R P, Schiff E R, Davis G L et al.. A randomized controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B.  N Engl J Med. 1990;  323 295-301
• 6 Niederau C, Heintges T, Lange S et al.. Long term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B.  N Engl J Med. 1996;  334 1422-1427
• 7 Dienstag J L, Schiff E R, Wright T L et al.. Lamivudine as initial treatment for chronic hepatitis B in the United States.  N Engl J Med. 1999;  341 1256-1263
• 8 Lai C L, Chien R N, Leung N WY et al.. A one-year trial of lamivudine for chronic hepatitis B.  N Engl J Med. 1998;  339 61-68
• 9 Dienstag J L, Goldin R D, Heathcote E J et al.. Histological outcome during long-term lamivudine therapy.  Gastroenterology. 2003;  124 105-117
• 10 Heathcote E J, Jeffers L, Wright T et al.. Loss of serum HBV DNA and HBeAg and seroconversion following short-term (12 weeks) adefovir dipivoxil therapy in chronic hepatitis B: two placebo-controlled phase II studies.  Hepatology. 1998;  28(Suppl) 317A
• 11 Marcellin P, Chang T T, Lim S G et al.. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.  N Engl J Med. 2003;  348 808-816
• 12 Hadziyannis S J, Nicolaos C T, Heathcote E J et al.. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.  N Engl J Med. 2003;  348 800-807
• 13 Peters M, Hann H W, Martin P et al.. Adefovir dipivoxil (ADV) alone and in combination with lamivudine (LAM) suppresses YMDD mutant hepatitis B virus replication: 48 week preliminary analysis.  Hepatology. 2002;  36(Suppl 2) 374A
• 14 Westland C E, Yang H, Delaney IV W E et al.. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B.  Hepatology. 2003;  38 96-103
• 15 Xiong S, Yang H, Westland C E et al.. Resistance surveillance of HBeAg-chronic hepatitis B patients treated for two years with adefovir dipivoxil.  J Hepatol. 2003;  38(Suppl 2) 628A